KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

Opinion
Video

Medical experts review long-term data from the KEYNOTE-B61 trial on pembrolizumab and lenvatinib, compare its efficacy and safety across non–clear cell RCC subtypes, and discuss dose management and safety relative to the CLEAR trial.

Video content above is prompted by the following:

  • Discuss the long-term follow-up data from the phase II 2 KEYNOTE-B61trial investigating pembrolizumab and lenvatinib and its the data’s impact in the first-line setting for advanced nccRCC.
    • How does the population size of this trial compare to with others?

Please comment on the recent label change based on this these data.

  • Building on the long-term follow-up data from the KEYNOTE-B61 trial, how did the response rates and safety data compare across different nccRCC histologies?
  1. In your practice, how do you approach dose reductions and treatment duration management?

How does the safety data seen in KEYNOTE B61 compare to with what is was seen in the CLEAR trial?

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content